3318 results about "Ethyl phosphate" patented technology

A method for treating a recirculating water system which comprises introducing into said water system a multifunctional, multilayer tablet, wherein the multilayer tablet comprises a fast dissolving layer and a slow dissolving layer, wherein said fast dissolving layer releases a combination of active ingredients including a member selected from the group consisting of lithium hypochlorite, calcium hypochlorite, trichloroisocyanuric acid (TCCA), anhydrous sodium dichloroisocyanurate, sodium persulfate, potassium persulfate, potassium monopersulfate, sodium monopersulfate, and mixtures thereof, and at least one of a clarifier, chelating agent, sequesterant, algaestat, water softener, algaecide, corrosion inhibitor, scale inhibitor, flocculent, disintegrant, dispersant, colorant, dissolution control agent, fragrance, or surfactant and, wherein said slow dissolving layer includes a member selected from the group consisting of trichloroisocyanuric acid (TCCA), calcium hypochlorite, 1,3-dichloro-5,5-dimethylhydantoin (DCDMH), 1,3-dibromo-5,5-dimethylhydantoin (DBDMH), 1-bromo-3-chloro-5,5-dimethylhydantoin (BCDMH), 1,3-dichloro-5-ethyl-5-methylhydantoin (DCEMH), 1,3-dibromo-5-ethyl-5-methylhydantoin (DBEMH), 1-bromo-3-chloro-5-methyl-5-ethylhydantoin (BCEMH), and mixtures thereof, and at least one of a clarifier, chelating agent, sequesterant, algaestat, water softener, algaecide, corrosion inhibitor, scale inhibitor, flocculent, disintegrant, dispersant, colorant, dissolution control agent or surfactant.

A transdermal therapeutic system, comprising a backing layer inert to the components of the matrix, a self-adhesive matrix layer containing (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol in an effective amount and a protective foil or sheet to be removed prior to use, is characterised by a matrix that is based on a non-aqueous, acrylate-based or silicone-based polymer adhesive system having a solubility of ≧5% (w / w) for (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]-amino]-1-naphthalenol, and said matrix is substantially free of inorganic silicate particulates.

There are disclosed a method for removing CO2 from a combustion exhaust gas which comprises the step of bringing the combustion exhaust gas under atmospheric pressure into contact with an aqueous solution of a hindered amine selected from the group consisting of 2-amino-2-methyl-1-propanol, 2-methylaminoethanol, 2-ethylamino-ethanol and 2-piperidineethanol; and another method for removing carbon dioxide from a combustion exhaust gas which comprises the step of bringing the combustion exhaust gas under atmospheric pressure into contact with a mixed aqueous solution of 100 parts by weight of an amine compound (X) selected from the group consisting of 2-amino-2-methyl-1, 3-propanediol, 2-amino-2-methyl-1-propanol, 2-amino-2-ethyl-1, 3-propanediol, t-butyldiethanolamine and 2-amino-2-hydroxymethyl-1,3-propanediol; and 1-25 parts by weight of an amine compound (Y) selected from the group consisting of piperazine, piperidine, morpholine, glycine, 2-methylamino-ethanol, 2-piperidineethanol and 2-ethylaminoethanol.

Multilayer, positive working, thermally imageable elements are disclosed. The elements produce bakeable lithographic printing plates that are resistant to press chemistries. The elements have a substrate, an underlayer, and a top layer. The underlayer comprises a resin or resins having activated methylol and / or activated alkylated methylol groups, such as a resole resin, and a polymeric material that comprises, in polymerized form, (a) methacrylic acid; (b) N-phenylmaleimide, N-cyclohexylmaleimide, N-benzylmaleimide, or a mixture thereof; and (c) one or more monomers of the structure: in which:R1 is H or methyl; X is —(CH2)n—, where n is an integer from 2 to 12; —(CH2—CH2—O)p—CH2—CH2—, where p is an integer from 1 to 3; or —Si(R′)(R″)— where R′ and R″ are each independently methyl or ethyl; and m is 1, 2, or 3.

Compounds, compositions, and methods relating to 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine or a pharmaceutically acceptable salt thereof are provided for the treatment of Type II diabetes and other diseases associated with poor glycemic control.